Metoprolol-d6 (tartrate) |
Catalog No.GC47669
One-Click Copy Product Info
|
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Metoprolol-d6 is intended for use as an internal standard for the quantification of metoprolol by GC- or LC-MS. Metoprolol is a potent and selective β1-adrenergic receptor (β1-AR) antagonist (Ki = 47 nM).1 It is selective for β1- over β2- and β3-ARs (Kis = 2.96 and 10.1 μM, respectively). In vivo, metoprolol (2.5 mg/kg per hour) reduces aortic atherosclerotic plaque area, serum levels of TNF-α and CXCL1, and plaque macrophage content in an ApoE-/- mouse model of atherosclerosis.2 Metoprolol (1 mg/kg per day) reduces biventricular cavity expansion and myocardial necrosis in a mouse model of encephalomyocarditis-induced congestive heart failure when administered in combination with captopril .3 Formulations containing metoprolol have been used in the treatment of high blood pressure and heart failure.
1.Hoffmann, C., Leitz, M.R., Oberdorf-Maass, S., et al.Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cellsNaunyn Schmiedebergs Arch. Pharmacol.369(2)151-159(2004) 2.Ulleryd, M.A., Bernberg, E., Yang, L.J., et al.Metoprolol reduces proinflammatory cytokines and atherosclerosis in ApoE-/- mice.Biomed. Res. Int.548783(2014) 3.Kanda, T., Inoue, M., Suzuki, T., et al.Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice.Cardiovasc. Drugs Ther.7(5)795-800(1993)
| Cas No. | N/A | SDF | |
| Canonical SMILES | COCCC1=CC=C(C=C1)OCC(CNC(C([2H])([2H])[2H])C([2H])([2H])[2H])O.OC(C(C(C(O)=O)O)O)=O.COCCC2=CC=C(C=C2)OCC(CNC(C([2H])([2H])[2H])C([2H])([2H])[2H])O | ||
| Formula | C15H19D6NO3.1/2C4H6O6 | M.Wt | 348.5 |
| Solubility | DMSO: soluble,Methanol: soluble,Water: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8694 mL | 14.3472 mL | 28.6944 mL |
| 5 mM | 573.9 μL | 2.8694 mL | 5.7389 mL |
| 10 mM | 286.9 μL | 1.4347 mL | 2.8694 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)